<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> FR89322-0203 </DOCNO><DOCID>fr.3-22-89.f2.A1202</DOCID><TEXT><ITAG tagnum="94"><ITAG tagnum="69"><ITAG tagnum="50">DEPARTMENT OF JUSTICE</ITAG><ITAG tagnum="18">Drug Enforcement Administration</ITAG><ITAG tagnum="52">Manufacturer of Controlled Substances; Application </ITAG>Pursuant to andSection;1301.43(a) of Title 21 of the Code of Federal Regulations(CFR), this is notice that on January 12, 1989, Mallinckrodt, SpecialtyChemicals Company, Mallinckrodt and Second Street, St. Louis, Missouri63147, made application to the Drug Enforcement Administration (DEA) forregistration as a bulk manufacturer of the basic classes of controlledsubstances listed below:<ITAG tagnum="110"><C>2,L1,tp0,i1,r75,8 </C> <H1>Drug </H1><H1>Schedule</H1><ITAG tagnum="1">Cocaine (9041) <D>II</D></ITAG><ITAG tagnum="1">Codeine (9050) <D>II</D></ITAG><ITAG tagnum="1">Diprenorphine (9058) <D>II</D></ITAG><ITAG tagnum="1">Etorphine hydrochloride (9059) <D>II</D></ITAG><ITAG tagnum="1">Dihydrocodeine (9120) <D>II</D></ITAG><ITAG tagnum="1">Oxycodone (9143) <D>II</D></ITAG><ITAG tagnum="1">Hydromorphone (9150) <D>II</D></ITAG><ITAG tagnum="1">Diphenoxylate (9170) <D>II</D></ITAG><ITAG tagnum="1">Hydrocodone (9193) <D>II</D></ITAG><ITAG tagnum="1">Levorphanol (9220) <D>II</D></ITAG><ITAG tagnum="1">Methadone (9250) <D>II</D></ITAG><ITAG tagnum="1">Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane(9254) <D>II</D></ITAG><ITAG tagnum="1">Bulk dextropropoxyphene (non-dosage forms) (9273) <D>II</D></ITAG><ITAG tagnum="1">Morphine (9300) <D>II</D></ITAG><ITAG tagnum="1">Thebaine (9333) <D>II</D></ITAG><ITAG tagnum="1">Opium extracts (9610) <D>II</D></ITAG><ITAG tagnum="1">Opium fluid extracts (9620 <D>II</D></ITAG><ITAG tagnum="1">Tincture of opium (9630) <D>II</D></ITAG><ITAG tagnum="1">Powdered opium (9639) <D>II</D></ITAG><ITAG tagnum="1">Granulated opium (9640) <D>II</D></ITAG><ITAG tagnum="1">Oxymorphone (9652) <D>II</D></ITAG><ITAG tagnum="1">Fentanyl (9801) <D>II</D></ITAG></ITAG> Any other such applicant and any person who is presently registered withDEA to manufacture such substances may file comments or objections to theissuance of the above application and may also file a written request fora hearing thereon in accordance with 21 CFR 1301.54 and in the form prescribedby 21 CFR 1316.47. Any such comments, objections or requests for a hearing may be addressedto the Deputy Assistant Administrator, Drug Enforcement Administration,United States Department of Justice, 1405 I Street, NW., Washington, DC20537, Attention: DEA Federal Register Representative (Room 1112), andmust be filed no later than April 21, 1989.<ITAG tagnum="21">Dated: March 16, 1989. </ITAG><ITAG tagnum="6">Gene R. Haislip, </ITAG><ITAG tagnum="4">Deputy Assistant Administrator, Office of Diversion Control, Drug EnforcementAdministration.</ITAG><ITAG tagnum="40">[FR Doc. 89-6654 Filed 3-21-89; 8:45 am]</ITAG><ITAG tagnum="68">BILLING CODE 4410-09-M</ITAG></ITAG></ITAG></TEXT></DOC>